Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.31 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.30 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL841848 | 1.00 | LMNA (0.42) | LMNACYP2C9MAPK1OPRM1CCR5 | |
| Hydrochloric Acid SCHEMBL272255 | 1.00 | LMNA (0.42) | LMNACYP2C9MAPK1OPRM1CCR5 | |
| Hydrochloric Acid SCHEMBL21378869 | 1.00 | LMNA (0.42) | LMNACYP2C9MAPK1OPRM1CCR5 | |
| SCHEMBL16382274 | 0.97 | — | — | |
| SCHEMBL12029112 | 0.97 | — | — | |
| SCHEMBL272039 | 0.97 | — | — | |
| SCHEMBL12208387 | 0.97 | — | — | |
| Bromide SCHEMBL29867591 | 0.94 | LMNA (0.42) | LMNACYP2C9MAPK1OPRM1CCR5 | |
| Hydrochloric Acid SCHEMBL274610 | 0.89 | MAPK1 (0.44) | LMNACYP2C9MAPK1HTR6 | |
| SCHEMBL701588 | 0.86 | MAPK1 (0.46) | LMNACYP2C9MAPK1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-113527335-B | Macrocyclic compound as EGFR inhibitor and application thereof | 南京圣和药业股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | LISEN THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4446325-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shandong Luye Pharmaceutical Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| EP-4139296-B1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-09-18 | — | — | EP | disclosed |
| CN-118382626-A | Protein kinase inhibitor and preparation method and application thereof | 山东绿叶制药有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444488-A | Pyrimidine-2, 4-diamine derivative and preparation method and application thereof | 上海立森印迹医药技术有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-116323588-A | Compounds and methods for CD73 modulation and indications therefor | 奥普纳生物有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023104178-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 山东绿叶制药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-4139296-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Immuno Oncology, SA (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
| WO-2021216898-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-5190955-A | Bactericides, effective against antibiotic resistant germs | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | OPRM1 655/4885CCR5 1311/4885HTR6 738/4885 |
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | OPRM1 2357/4885CCR5 3711/4885HTR6 646/4885 |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | DPYD, TYMP, TYMS | OPRM1 1850/4885CCR5 2459/4885HTR6 2290/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | OPRM1 3795/4885CCR5 3343/4885HTR6 2405/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | OPRM1 646/4885CCR5 1284/4885HTR6 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.